Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide versus insulin glulisine added to basal insulin in type 2 diabetes
2012-004096-38Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lixisenatide and insulin glulisine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in HbA1c. Started Dec 2012; status: completed.
02
Drugs
lixisenatideinsulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004096-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004096-38.